DIJON, France & LEUVEN, Belgium & PARIS--(BUSINESS WIRE)--Regulatory News: Oncodesign, a Drug Discovery company and oncology pharmacology service provider, and the Laboratory for Neurobiology and Gene Therapy (LNGT) at the Department of Neurosciences at the KU Leuven, an expert academic group exploring the roles of LRRK2 and a-synuclein in Parkinson’s disease headed by Professor Veerle Baekelandt, today announced that they have entered into a research collaboration to evaluate, with Ipsen (Euronext: IPN, ADR: IPSEY) (Paris:IPN), Oncodesign’s compounds in multiple pharmacology models for Parkinson’s disease. The collaboration builds on Oncodesign’s LRRK2 program with advanced Nanocyclix® lead molecules that was partnered with Ipsen in January 2012. “Our partnership with Ipsen on the discovery of novel therapeutic agents in Parkinson’s disease has advanced to a stage where we can use further in depth expertise and advanced pharmacology models to position our leads. We are very excited to collaborate with KU Leuven to advance our understanding of both our inhibitors and the LRRK2 target”, said Jan Hoflack, Ph.D., Chief Scientific Officer and Head of Oncodesign’s Discovery Activities.
